Skip to Content

MVASI Dosage

Generic name: BEVACIZUMAB-AWWB 100mg in 4mL
Dosage form: injection, solution

Medically reviewed by Last updated on Sep 20, 2017.


Administer only as an intravenous (IV) infusion. Do not administer as an intravenous push or bolus.

  • Do not initiate MVASI until at least 28 days following major surgery. Administer MVASI after the surgical incision has fully healed.
  • First infusion: Administer infusion over 90 minutes.
  • Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated; administer all subsequent infusions over 30 minutes if infusion over 60 minutes is tolerated.

Recommended Doses and Schedules

Patients should continue treatment until disease progression or unacceptable toxicity.

Metastatic Colorectal Cancer (mCRC)

The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.

  • Administer 5 mg/kg every 2 weeks when used in combination with bolus-IFL.
  • Administer 10 mg/kg every 2 weeks when used in combination with FOLFOX4.
  • Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line bevacizumab product-containing regimen.

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.


The recommended dose is 10 mg/kg every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC)

The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.

Cervical Cancer

The recommended dose of MVASI is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.

Preparation for Administration

Use appropriate aseptic technique. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. MVASI is a colorless to pale yellow solution. Do not use vial if solution is cloudy, discolored, or contains particulate matter.

Withdraw necessary amount of MVASI and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. Discard any unused portion left in a vial, as the product contains no preservatives.

Diluted MVASI solutions may be stored at 2-8ºC (36-46°F) for up to 8 hours.


Dose Modifications

There are no recommended dose reductions.
Discontinue MVASI for:

  • Gastrointestinal perforations (gastrointestinal perforations, fistula formation in the gastrointestinal tract, intra-abdominal abscess), fistula formation involving an internal organ [see Boxed Warning, Warnings and Precautions (5.1, 5.2)].
  • Wound dehiscence and wound healing complications requiring medical intervention [see Warnings and Precautions (5.3)].
  • Serious hemorrhage (i.e., requiring medical intervention) [see Boxed Warning, Warnings and Precautions (5.4)].
  • Severe arterial thromboembolic events [see Warnings and Precautions (5.5)].
  • Life-threatening (Grade 4) venous thromboembolic events, including pulmonary embolism [see Warnings and Precautions (5.6)].
  • Hypertensive crisis or hypertensive encephalopathy [see Warnings and Precautions (5.7)].
  • Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.8)].
  • Nephrotic syndrome [see Warnings and Precautions (5.9)].

Temporarily suspend MVASI for:

  • At least 4 weeks prior to elective surgery [see Warnings and Precautions (5.3)].
  • Severe hypertension not controlled with medical management [see Warnings and Precautions (5.7)].
  • Moderate to severe proteinuria [see Warnings and Precautions (5.9)].
  • Severe infusion reactions [see Warnings and Precautions (5.10)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions